Advertisement
YOU ARE HERE: LAT HomeCollectionsVertex Pharmaceuticals Inc
IN THE NEWS

Vertex Pharmaceuticals Inc

FEATURED ARTICLES
BUSINESS
November 8, 2003
* Berkshire Hathaway Inc., the investment company run by billionaire Warren E. Buffett, said third-quarter profit increased 58% to $1.8 billion, or $1,176 a share, from $1.14 billion, or $744, a year earlier. Revenue climbed 72% to $18.2 billion, partly from the purchase of food distributor McLane Co. * Chiron Corp. agreed to settle a lawsuit that claimed Vertex Pharmaceuticals Inc. violated patents on a treatment for the hepatitis C virus.
ARTICLES BY DATE
BUSINESS
November 8, 2003
* Berkshire Hathaway Inc., the investment company run by billionaire Warren E. Buffett, said third-quarter profit increased 58% to $1.8 billion, or $1,176 a share, from $1.14 billion, or $744, a year earlier. Revenue climbed 72% to $18.2 billion, partly from the purchase of food distributor McLane Co. * Chiron Corp. agreed to settle a lawsuit that claimed Vertex Pharmaceuticals Inc. violated patents on a treatment for the hepatitis C virus.
Advertisement
BUSINESS
December 25, 2003 | From Bloomberg News
Invitrogen Corp., a maker of chemical kits used to analyze and clone genes, agreed to buy BioReliance Corp. for $430 million to expand its production capabilities for biotechnology customers. Invitrogen will pay $48 a share, Tuesday's closing price, for BioReliance and assume about $70 million in debt, the companies said in a statement. Carlsbad-based Invitrogen expects the acquisition to be completed by April and to add about 19 cents a share to profit in 2004.
BUSINESS
May 1, 2001 | From Bloomberg News
Biotech firm Vertex Pharmaceuticals Inc. agreed to buy Aurora Biosciences Corp. for about $592 million in stock to gain tools and systems used to search for drug candidates. Vertex, based in Cambridge, Mass., said it will pay 0.62 share, or $24.34, for each Aurora share. That's 44% more than Aurora's closing price Friday of $16.85. The acquisition would join Aurora's biology technology with Vertex's chemical approaches to drug discovery and development.
NEWS
May 23, 2011 | By Thomas H. Maugh II, Los Angeles Times/For the Booster Shots blog
The Food and Drug Administration on Monday approved telaprevir for the treatment of hepatitis C, the second drug for the disease approved in two weeks. On May 13, the agency approved boceprevir, sold under the brand name Victrelis. The two drugs are the first new treatments for hepatitis C in 20 years. Both are members of a new class of drugs called protease inhibitors that block replication of an enzyme that is crucial to the replication of the virus. Like boceprevir, telaprevir, sold under the brand name Incivek by Vertex Pharmaceuticals Inc. of Cambridge, Mass., is meant to be used only in conjunction with the standard therapy of peginterferon-alpha and ribavirin.
BUSINESS
May 30, 2001 | From Reuters
San Diego-based Sequenom Inc. said Tuesday it will buy Britain's Gemini Genomics for $228 million in stock, part of a wave of consolidation in the emerging genomics industry. Sequenom said the tie-up would combine its genotyping technology platform with Gemini's expertise in population genetics, expanding their potential for disease-gene discovery.
HEALTH
November 2, 2011 | By Amina Khan, Los Angeles Times
All her life, Lindsay Shipp knew that she was dying. As a baby, she would cry after eating, and salt collected on her forehead. The diagnosis was cystic fibrosis, an incurable genetic disease that, at the time, meant a life expectancy of 18 years. The disease, which affects 30,000 people in the United States, hinders the movement of salt in the body. Because of this, the pancreas fails soon after birth, patients cannot properly digest food, and their airways fill with mucus, leaving them vulnerable to lung infections and other problems.
Los Angeles Times Articles
|